Sponsor content
330 result(s) found, displaying 141 to 150
-
Australian public assessment report (AusPar)Forxiga (dapagliflozin) has been approved for reducing the risk of progressive decline in kidney function in adults with
proteinuric chronic kidney disease. -
-
Designation or determinationProvisional determination
-
-
Cancellation by sponsorRequested by AstraZeneca Pty Ltd
-
Australian public assessment report (AusPar)New AusPAR for EVUSHELD (tixagevimab and cilgavimab) for pre-exposure prophylaxis of COVID-19 in adults and adolescents aged 12 years older
-
Prescription medicine decision summaryTGA decision: Evusheld (tixagevimab/cilgavimab) is approved for the treatment of pre-exposure prophylaxis of COVID-19.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for BRICANYL TURBUHALER terbutaline sulfate 400 microgram powder for inhalation dry powder inhaler.
-
Prescription medicine registrationActive ingredients: cilgavimab; tixagevimab.
-
Prescription medicine registrationActive ingredients: cilgavimab; tixagevimab.